A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin
fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that
affects multiple organs, including the musculoskeletal, cardiac, pulmonary, and
gastrointestinal systems. Patients may experience many symptoms such as pain, fatigue,
dyspnea, impaired hand function, dry mouth, and difficulty sleeping. As a result of these
symptoms, these patients may experience a decrease in activities of daily living, physical
activity level and quality of life, while psychological problems such as anxiety and
depression may increase.